Nuveen’s Charles River Laboratories CRL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$27.5M Sell
121,079
-12,904
-10% -$2.3M 0.01% 1069
2026
Q1
$23.1M Buy
133,983
+7,163
+6% +$1.33M 0.01% 1049
2025
Q4
$25.3M Sell
126,820
-25,457
-17% -$4.62M 0.01% 1003
2025
Q3
$23.8M Sell
152,277
-650
-0.4% -$103K 0.01% 1040
2025
Q2
$23.2M Buy
152,927
+29,767
+24% +$3.97M 0.01% 1010
2025
Q1
$18.5M Sell
123,160
-3,907
-3% -$655K 0.01% 1169
2024
Q4
$23.5M Sell
127,067
-1,770
-1% -$341K 0.01% 1077
2024
Q3
$25.4M Sell
128,837
-1,162
-0.9% -$241K 0.01% 1027
2024
Q2
$26.9M Sell
129,999
-4,578
-3% -$1.04M 0.01% 938
2024
Q1
$36.5M Sell
134,577
-46,173
-26% -$11M 0.01% 791
2023
Q4
$42.7M Buy
180,750
+109
+0.1% +$21.4K 0.01% 679
2023
Q3
$35.4M Sell
180,641
-1,711
-0.9% -$351K 0.01% 718
2023
Q2
$38.3M Sell
182,352
-34,393
-16% -$6.84M 0.01% 684
2023
Q1
$43.7M Buy
216,745
+8,337
+4% +$1.89M 0.02% 606
2022
Q4
$45.4M Sell
208,408
-30,564
-13% -$6.67M 0.02% 574
2022
Q3
$47M Sell
238,972
-70,742
-23% -$15.3M 0.02% 541
2022
Q2
$66.3M Sell
309,714
-32,118
-9% -$7.85M 0.03% 459
2022
Q1
$98M Buy
341,832
+68,471
+25% +$21.1M 0.03% 423
2021
Q4
$103M Buy
273,361
+21,013
+8% +$8.16M 0.03% 434
2021
Q3
$104M Sell
252,348
-31,205
-11% -$13M 0.03% 416
2021
Q2
$105M Buy
283,553
+23,029
+9% +$7.69M 0.03% 460
2021
Q1
$75.5M Sell
260,524
-4,447
-2% -$1.24M 0.02% 550
2020
Q4
$66.2M Buy
264,971
+65,556
+33% +$15.6M 0.02% 568
2020
Q3
$45.2M Sell
199,415
-7,118
-3% -$1.48M 0.02% 612
2020
Q2
$36M Sell
206,533
-56,678
-22% -$9.05M 0.01% 687
2020
Q1
$33.2M Buy
263,211
+113,343
+76% +$17M 0.02% 639
2019
Q4
$22.9M Sell
149,868
-26,225
-15% -$3.63M 0.01% 1089
2019
Q3
$23.3M Sell
176,093
-27,096
-13% -$3.63M 0.01% 1049
2019
Q2
$28.8M Buy
203,189
+197,847
+3,704% +$26.8M 0.01% 958
2019
Q1
$776K Hold
5,342
﹤0.01% 778
2018
Q4
$605K Hold
5,342
﹤0.01% 791
2018
Q3
$719K Buy
5,342
+554
+12% +$68.4K ﹤0.01% 796
2018
Q2
$538K Hold
4,788
﹤0.01% 860
2018
Q1
$511K Hold
4,788
﹤0.01% 887
2017
Q4
$524K Hold
4,788
﹤0.01% 886
2017
Q3
$517K Sell
4,788
-474
-9% -$48.7K ﹤0.01% 901
2017
Q2
$532K Sell
5,262
-13,968
-73% -$1.29M ﹤0.01% 915
2017
Q1
$1.73M Sell
19,230
-3,632
-16% -$308K 0.01% 745
2016
Q4
$1.74M Sell
22,862
-1,937
-8% -$147K 0.01% 932
2016
Q3
$2.07M Sell
24,799
-32,300
-57% -$2.71M 0.01% 769
2016
Q2
$4.71M Buy
57,099
+31,800
+126% +$2.62M 0.03% 510
2016
Q1
$1.92M Sell
25,299
-12,200
-33% -$903K 0.01% 759
2015
Q4
$3.02M Buy
37,499
+13,174
+54% +$950K 0.02% 621
2015
Q3
$1.54M Hold
24,325
0.01% 887
2015
Q2
$1.71M Hold
24,325
0.01% 900
2015
Q1
$1.93M Hold
24,325
0.01% 865
2014
Q4
$1.55M Hold
24,325
0.01% 982
2014
Q3
$1.45M Sell
24,325
-152
-0.6% -$8.7K 0.01% 964
2014
Q2
$1.31M Sell
24,477
-1,473
-6% -$80.8K 0.01% 1020
2014
Q1
$1.57M Sell
25,950
-231
-0.9% -$13.5K 0.01% 913
2013
Q4
$1.39M Sell
26,181
-23,265
-47% -$1.17M 0.01% 940
2013
Q3
$2.29M Buy
49,446
+26,632
+117% +$1.22M 0.01% 743
2013
Q2
$936K Buy
+22,814
New +$977K 0.01% 1062

Other funds holding CRL

Nuveen's CRL Position: Q2 2026 in Review

Nuveen reduced its Charles River Laboratories (CRL) stake by 9.6% in Q2 2026, selling an estimated $2.3M and leaving 121,079 shares worth $27.5M. The position accounts for 0.01% of the portfolio, ranked #1069.

Nuveen first reported a position in CRL in Q2 2013 and has held it in 53 quarters since. The position peaked at $105M in Q2 2021. 565 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

  • Nuveen held 121,079 shares of Charles River Laboratories worth $27.5M as of Q2 2026.
  • Nuveen sold 12,904 Charles River Laboratories shares in Q2 2026, an estimated $2.3M.
  • Charles River Laboratories made up 0.01% of Nuveen's portfolio in Q2 2026, its #1069 holding.
  • Nuveen first reported a position in Charles River Laboratories in Q2 2013 and has held it in 53 quarters since.
  • Nuveen's Charles River Laboratories position peaked at $105M in Q2 2021.
  • 565 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.